Galderma Acne Ingredient Rx-to-OTC Switch Headed For NDAC In April
This article was originally published in The Rose Sheet
Executive Summary
FDA schedules an April 15 NDAC meeting to consider whether data in Galderma's supplemental NDA support an acceptable risk/benefit profile for nonprescription use of adapalene gel 0.1.
You may also be interested in...
Merck Silence On OTC Singulair Speaks Volumes On Switch Outlook
Merck & Co.’s silence on an OTC version of Singulair is a sign of the relatively “quiet” 2015 switch market despite the call for novel switches, particularly to treat chronic conditions, from FDA’s Nonprescription Drug Safe Use Regulatory Expansion Initiative.
Dermatology Among Emerging Rx-To-OTC Switch Categories
FDA threw the switch floodgates open with the Nonprescription Safe Use Regulatory Expansion (NSURE) initiative and has fueled interest with recent first-in-class switches of Nasacort and Oxytrol for Women. Experts say likely categories for successful switches include dermatology, as drugs for treating eczema, acne and other skin conditions typically do not have systemic effects and address ailments that are readily recognized and understood by consumers.
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.